The Central Council for Research in Homeopathy (CCRH), the autonomous body under AYUSH, has called for further research to promote this system of medicine, said Dr R K Manchanda, Director General of CCRH.
This comes against the backdrop of the World Homeopathy Summit hosted by Global Homeopathy Foundation in collaboration with the CCRH which saw participation of scientists and practitioners from India and abroad.
The research work at the summit yielded information of genomics which can be juxtaposed on effect of homeopathic medicines individualised at molecular level, he said.
The CCRH has found out that integration of homeopathic and allopathic medicines has proved to be successful in tackling Multidrug-resistant Tuberculosis (MDR-TB).
He expressed happiness at the huge participation of scientists from Brazil, Italy as well India's ICMR, IIT-B, ICT, IICT, Bose, Haffkine and CSIR at the summit to prove that homeopathy is not a "placebo medicine" but science.
"The deliberations at the summit held recently and the ocean of information on the research done into treatment of AIDS, cancer, influenza and TB and the detection of nanoparticles in homeopathic medicines will definitely take homeopathy to a new dimension altogether," he said.
Researchers at the summit had established that homeopathic medicine made from venom of rattlesnake can arrest spread of HIV while another research group demonstrated that cancer tumor regressed significantly after administering homeopathic nanoparticles of Calcaria Carbonicum.
The summit saw participants seeking to dispel the myth and disinformation by a section that homeopathy is a "humbug" and that it has only a placebo effect.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
